The latest version of the National Comprehensive Cancer Network (NCCN) guidelines for NSCLC recommends that, in addition to detecting EGFR, KRAS, BRAF, HER2 mutations, MET amplification/exon 14 skipping mutations and gene rearrangements involving ROS1, RET, ALK, etc., NTRK gene fusion should also be genetically tested. This evidence concerns the gene BRAF and non-small cell lung carcinoma.